Previous Close | 9.97 |
Open | 10.00 |
Bid | 0.00 x 800 |
Ask | 0.00 x 900 |
Day's Range | 9.70 - 10.11 |
52 Week Range | 8.63 - 17.24 |
Volume | 50,989 |
Avg. Volume | 112,100 |
Market Cap | 138M |
Beta (5Y Monthly) | 0.39 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.10 |
Earnings Date | Nov 5, 2019 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 21.67 |
OptimizeRx Corp. (OPRX), a leading provider of digital health solutions for pharmaceutical companies, payers, medtech and medical associations, reported its sales pipeline, which is comprised of outstanding request for proposals (RFPs) submitted, has increased 79% to $84 million in 2019 as compared to last year. The company’s RFPs have historically realized a 35%-50% close rate. “Our sales pipeline growth is being driven by an accelerated migration to digital solutions by pharma, along with a greater focus on patient experience,” noted Stephen Silvestro, chief commercial officer of OptimizeRx.
Q3 2019 OPTIMIZERx Corp Earnings Call
ROCHESTER, Mich., Nov. 05, 2019 -- OptimizeRx Corp. (NASDAQ: OPRX), a leading provider of digital health solutions for pharmaceutical companies, payers, medtech and medical.
Will Febbo became the CEO of OptimizeRx Corporation (NASDAQ:OPRX) in 2016. First, this article will compare CEO...
OptimizeRx Corp. (OPRX), a leading provider of digital health solutions for pharmaceutical companies, payers, medtech and medical associations, has integrated its core set of solutions into a single platform to more effectively address the need for greater patient-provider-pharma-payer collaboration and improvement in medication affordability and adherence. OptimizeRx recently announced the acquisition of the digital therapeutics SaaS provider, RMDY Health, as well as an exclusive three-year partnership with NewCrop, a provider of integrated electronic prescribing software. “Following our latest acquisitions where we entered the additional payer and medical device market, we have now brought together all of our existing and newest offerings onto a single platform with touchpoints throughout the care journey,” said Steve Silvestro, chief commercial officer at OptimizeRx.
ROCHESTER, Mich., Oct. 24, 2019 -- OptimizeRx Corp. (NASDAQ: OPRX), a leading provider of digital health solutions for pharmaceutical companies, payers, medtech companies and.
ROCHESTER, Mich., Oct. 22, 2019 -- OptimizeRx Corp. (NASDAQ: OPRX), a leading provider of digital health solutions for payers, medtech companies, medical associations and the.
OptimizeRx Corp. (OPRX), a leading platform for digital health messaging in the pharmaceutical industry, is sponsoring the WOMEN at HLTH program at HLTH 2019, the nation’s largest conference focused on health innovation. HLTH is a one-of-a-kind ecosystem event for the health industry, bringing together more than 5,000 senior leaders to address the most pressing problems facing healthcare today. WOMEN at HLTH is a series of activities at HLTH focused on advancing and empowering women.
Q2 2019 OPTIMIZERx Corp Earnings Call
OptimizeRx Corp. (OPRX), a leading provider of digital health solutions for payers, medtech companies, medical associations and the pharmaceutical industry, has secured a three-year exclusive partnership with NewCrop, a provider of integrated electronic prescribing software, to deliver real-time digital health messages to NewCrop’s e-prescribing network of more than 65,000 healthcare professionals. The agreement builds upon a long standing, profitable relationship between the two partners, and solidifies OptimizeRx as the largest digital platform connecting life sciences to the point-of-care.
OptimizeRx Corp. (OPRX), a leading provider of digital health messaging for the pharmaceutical industry, will host two plenary sessions at the 13th Annual Digital Pharma East conference being held at the Pennsylvania Convention Center in Philadelphia on September 17-20, 2019. Bringing together more than 1,000 participants, this conference will feature latest case studies and senior-level discussions with pharma companies, health systems, physicians, health-tech companies, startups and non-traditional healthcare companies involved in digital health. The first plenary session, “Success in Today’s Evolving Pharma Marketing Landscape,” will be hosted by Steve Silvestro, chief commercial officer of OptimizeRx, at 11:00 a.m. Eastern time on September 17.
Zacks.com featured highlights include: Digital Turbine, Perion, Controladora Vuela, OptimizeRx and Eldorado Gold
This method involved zeroing in on those stocks whose prices are varying within a narrow band.
OptimizeRx Corp. (OPRX) to acquire RMDY Health, a multipurpose digital therapeutics SaaS platform, for $16 million in cash and equity. The RMDY Health platform is used by pharma, payers, MedTech companies and medical associations nationwide.
Building up an investment case requires looking at a stock holistically. Today I've chosen to put the spotlight on...
OptimizeRx Corp. (OPRX), a leading provider of digital health messaging for the pharmaceutical industry, has been invited to participate in the Lake Street Capital Markets 3rd Annual Best Ideas Growth (BIG3) Conference being held on September 12, 2019 at the Parker New York. The company’s digital health network is expanding into the acute care market after reaching more than half of the ambulatory patient market in the U.S. The event is for institutional clients of Lake Street and is by invitation only.
Generally speaking, investors are inspired to be stock pickers by the potential to find the big winners. You won't get...
ROCHESTER, Mich., Aug. 07, 2019 -- OptimizeRx Corp. (NASDAQ: OPRX), a leading provider of digital health messaging for the pharmaceutical industry, reported results for the.
Is (OPRX) Outperforming Other Computer and Technology Stocks This Year?
OptimizeRx's (OPRX) second-quarter 2019 results are likely to benefit from increased sales of core financial and brand messaging products.
OptimizeRx (OPRX) closed the most recent trading day at $15.09, moving +0.8% from the previous trading session.
OptimizeRx (OPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
In the latest trading session, OptimizeRx (OPRX) closed at $15.11, marking a -0.66% move from the previous day.
ROCHESTER, Mich., July 24, 2019 -- OptimizeRx Corp. (Nasdaq: OPRX), a leading platform for digital health messaging in the pharmaceutical industry, will hold a conference call.